Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 20 August 2025Expected publication date: 10 September 2025